Vanda Pharmaceuticals Inc. (VNDA) has announced the results from a second Phase III study of tradipitant in the treatment of motion sickness. These findings reinforce previously reported results from two other efficacy studies, demonstrating that tradipitant is effective in preventing vomiting associated with motion sickness. Vanda plans to submit a New Drug Application (NDA) for tradipitant to the FDA in the fourth quarter of 2024, aiming to address vomiting induced by motion sickness.
The Motion Serifos study was a multicenter, double-blind, placebo-controlled trial involving 316 participants. The study groups received either 170 mg of tradipitant, 85 mg of tradipitant, or a placebo. Both the 170 mg and 85 mg doses of tradipitant were found to be significantly more effective than the placebo in preventing vomiting.
For more health news, visit rttnews.com.
